Table 1.
Laboratory data on admission.
| Blood count | Blood chemistry | Tumor markers | |||
|---|---|---|---|---|---|
| WBC (3.5–5.5) | 8.15 × 109/L | ALT (9–50) | 92.3 U/L | AFP (0–8.1) | 4.97 ng/mL |
| RBC (4.3–5.8) | 3.58 × 1012/L | AST (15–40) | 125.0 U/L | CEA (0–5) | 1.50 ng/mL |
| NEUT# (2–7.7) | 6.08 × 109/L | S/L | 1.4 | CA125 (0–35) | 149.6 U/mL |
| NEUT% (45–77) | 74.7% | GGT (10–60) | 1164.0 U/L | CA153 (0–25) | 10.81 U/mL |
| LYMPH# (0.8–4.0) | 1.0 × 109/L | ALP (45–125) | 882.5 U/L | CA199 (0–27) | 32.03 U/mL |
| LYMPH% (20–40) | 12.3% | TBIL (1.7–17.1) | 249.0 µmol/L | CA72–4 (0–6.9) | 13.87 U/mL |
| EO# (0.05–0.5) | 0.03 × 109/L | DBIL (0–6.9) | 221.4 µmol/L | TPSA (0–4) | 0.929 ng/mL |
| EO% (0.5–5.0) | 0.3% | IBIL (1.7–10.2) | 27.6 µmol/L | FPSA (0–0.93) | 0.3 ng/mL |
| BASO# (0.0–0.1) | 0.02 × 109/L | TP (65–85) | 67.5 g/L | F/P | 0.32 |
| BASO% (0.0–1.0) | 0.2% | ALB (40–55) | 36.7 g/L | FERRITIN (30–400) | 493.20 ng/mL |
| HGB (130–175) | 108g/L | GLOB (20–40) | 30.8 g/L | CYFRA21–1 (0–3.3) | 19.35 ng/mL |
| HCT (40–50) | 32.60 | A/G (1.2–2.4) | 1.2 Ratio | NSE (0–16.3) | 279.1 ng/mL |
| PLT (125–350) | 236 × 109/L | TBA (0–10) | 318.07 µmol/L | ProGRP (≤65.7) | 40.2 pg/mL |
| CHE (5000–12,000) | 3196 U/L | ||||
AFP = alpha-fetoprotein, ALB = albumin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate transaminase, BASO = basophilicgranulocyte, CA = carbohydrate antigen, CEA = carcinoembryonic antigen, CHE = cholinesterase, CYFRA21-1 = cytokeratin 19 fragment antigen21-1, DBIL = direct bilirubin, EO = eosnophils, FPSA = free prostate specific antigen, GGT = γ-glutamyl transpeptadase, GLOB = globulin, HCT = red blood cell specific volume, HGB = hemoglobin, IBIL = Indirect bilirubin, LYMPH = lymphocyte, NEUT = neutrophil, NSE = neuron specific enolase, PLT = platelet, ProGRP = pro-gastrin-releasing peptide, RBC = red blood cell, TBA = total biliary acid, TBIL = total bilirubin, TP = total protein, TPSA = total prostate specific antigen, WBC = white blood cell.